PPARγ and human metabolic disease

Journal of Clinical Investigation

Volumn 116, Issue 3, 2006, Pages 581-589

  Semple, Robert K ^a   Chatterjee, V Krishna K ^b   O'Rahilly, Stephen ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; TROGLITAZONE; XENOBIOTIC AGENT;

CARBOHYDRATE METABOLISM; FLUID RETENTION; GENE MUTATION; GENETIC VARIABILITY; HEART FAILURE; HEMODILUTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIDE EFFECT;

HUMANS; METABOLIC DISEASES; PPAR GAMMA;

EID: 33644644599     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28003     Document Type: Review

References (125)

1. Issemann, I., and Green, S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Proc. Natl. Acad. Sci. U. S. A. 47:645-650.
2. Cunard, R., et al. 2004. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J. Immunol. 172:7530-7536.
3. Gervois, P., et al. 2001. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J. Biol. Chem. 276:33471-33477.
4. Bell-Parikh, L.C., et al. 2003. Biosynthesis of 15-deoxy-δ12,14- PGJ2 and the ligation of PPARγ. J. Clin. Invest. 112:945-955. doi:10.1172/JCI200318012.
5. Tzameli, I., et al. 2004. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem. 279:36093-36102.
6. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-1234.
7. Vidal-Puig, A.J., et al. 1997. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416-2422.
8. Fajas, L., et al. 1997. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272:18779-18789.
9. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147-1156.
10. Sandouk, T., Reda, D., and Hofmann, C. 1993. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am. J. Physiol. 264:C1600-C1608.
11. Kletzien, R.F., Clarke, S.D., and Ulrich, R.G. 1992. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41:393-398.
12. Ren, D., Collingwood, T.N., Rebar, E.J., Wolffe, A.P., and Camp, H.S. 2002. PPARgamma knockdown by engineered transcription factors: exogenous PPAR-gamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev. 16:27-32.
13. Mueller, E., et al. 2002. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J. Biol. Chem. 277:41925-41930.
14. Barak, Y., et al. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
15. Rosen, E.D., et al. 1999. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4:611-617.
16. Vidal-Puig, A., et al. 1996. Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97:2553-2561.
17. Schoonjans, K., et al. 1996. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336-5348.
18. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N. 1998. Expression of putative FA transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273:16710-16714.
19. Tordjman, J., et al. 2003. Thiazolidinediones block FA release by inducing glyceroneogenesis in fat cells. J. Biol. Chem. 278:18785-18790.
20. Tontonoz, P., Hu, E., Devine, J., Beale, E.G., and Spiegelman, B.M. 1995. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15:351-357.
21. Olswang, Y., et al. 2002. A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc. Natl. Acad. Sci. U. S. A. 99:625-630.
22. Glorian, M., et al. 2001. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie. 83:933-943.
23. Guan, H.P., et al. 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8:1122-1128.
24. Tan, G.D., et al. 2003. A "futile cycle" induced by thiazolidinediones in human adipose tissue? Nat. Med. 9:811-812; author reply 812.
25. Loviscach, M., et al. 2000. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia. 43:304-311.
26. Auboeuf, D., et al. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1319-1327.
27. Xu, H., et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821-1830. doi:10.1172/JCI200318012.
28. Weisberg, S.P., et al. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112:1796-1808. doi:10.1172/JCI200318012.
29. Spiegelman, B.M., and Heinrich, R. 2004. Biological control through regulated transcriptional coactivators. Cell. 119:157-167.
30. Lehmann, J.M., et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12953-12956.
31. Inzucchi, S.E., et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338:867-872.
32. Maggs, D.G., et al. 1998. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128:176-185.
33. Frias, J.P., Yu, J.G., Kruszynska, Y.T., and Olefsky, J.M. 2000. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care. 23:64-69.
34. Miyazaki, Y., et al. 2001. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 24:710-719.
35. Miyazaki, Y., et al. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87:2784-2791.
36. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193.
37. Sironi, A.M., et al. 1997. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin. Pharmacol. Ther. 62:194-202.
38. Suter, S.L., Nolan, J.J., Wallace, P., Gumbiner, B., and Olefsky, J.M. 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
39. Mudaliar, S., Chang, A.R., and Henry, R.R. 2003. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. 9:406-416.
40. Guan, Y., et al. 2005. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11:861-866.
41. Zhang, H., et al. 2005. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102:9406-9411.
42. Larsen, T.M., Toubro, S., and Astrup, A. 2003. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27:147-161.
43. van Harmelen, V., et al. 2002. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes. 51:2029-2036.
44. Sewter, C.P., Blows, F., Vidal-Puig, A., and O'Rahilly, S. 2002. Regional differences in the response of human pre-adipocytes to PPARgamma and RXR-alpha agonists. Diabetes. 51:718-723.
45. Adams, M., et al. 1997. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:3149-3153.
46. Jensen, M.D. 1997. Lipolysis: contribution from regional fat. Annu. Rev. Nutr. 17:127-139.
47. Garg, A. 2004. Regional adiposity and insulin resistance. J. Clin. Endocrinol. Metab. 89:4206-4210.
48. Ye, J.M., et al. 2004. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia. 47:1306-1313.
49. Raskin, P., et al. 2000. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 43:278-284.
50. Trujillo, M.E., and Scherer, P.E. 2005. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257:167-175.
51. Weyer, C., et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:1930-1935.
52. Yamamoto, Y., et al. 2002. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond.) 103:137-142.
53. Yu, J.G., et al. 2002. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 51:2968-2974.
54. Yang, W.S., et al. 2002. Plasma adiponectin levels in overweight and obese Asians. Obes. Res. 10:1104-1110.
55. Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N., and Ranganathan, G. 2003. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 52:1779-1785.
56. Maeda, N., et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2094-2099.
57. Yang, W.S., et al. 2002. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25:376-380.
58. Combs, T.P., et al. 2004. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 145:367-383.
59. Yang, Q., et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Proc. Natl. Acad. Sci. U. S. A. 36:356-362.
60. Yonemitsu, S., et al. 2001. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes. 50:1093-1101.
61. Ciaraldi, T.P., Gilmore, A., Olefsky, J.M., Goldberg, M., and Heidenreich, K.A. 1990. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1056-1062.
62. Yang, Z., Strickland, D.K., and Bornstein, P. 2001. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276:8403-8408.
63. Cha, B.S., et al. 2001. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia. 44:444-452.
64. Kausch, C., et al. 2001. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem. Biophys. Res. Commun. 280:664-674.
65. Norris, A.W., et al. 2003. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112:608-618. doi:10.1172/JCI200317305.
66. Hevener, A.L., et al. 2003. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9:1491-1497.
67. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
68. Edvardsson, U., et al. 1999. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid Res. 40:1177-1184.
69. Memon, R.A., et al. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 141:4021-4031.
70. Bedoucha, M., Atzpodien, E., and Boelsterli, U.A. 2001. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35:17-23.
71. Rahimian, R., et al. 2001. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol. Cell. Biochem. 224:29-37.
72. Yu, S., et al. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 278:498-505.
73. Neuschwander-Tetri, B.A., et al. 2003. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 38:434-440.
74. Sanyal, A.J., et al. 2004. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2:1107-1115.
75. Promrat, K., et al. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 39:188-196.
76. Barroso, I., et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Proc. Natl. Acad. Sci. U. S. A. 402:880-883.
77. Agarwal, A.K., and Garg, A. 2002. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87:408-411.
78. Hegele, R.A., Cao, H., Frankowski, C., Mathews, S.T., and Leff, T. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 51:3586-3590.
79. Agostini, M., et al. 2004. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology. 145:1527-1538.
80. Mori, Y., et al. 1999. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 22:908-912.
81. Kelly, I.E., Han, T.S., Walsh, K., and Lean, M.E. 1999. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 22:288-293.
82. Misra, A., Peethambaram, A., and Garg, A. 2004. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 83:18-34.
83. Savage, D.B., et al. 2003. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 52:910-917.
84. Savage, D.B., Murgatroyd, P.R., Chatterjee, V.K., and O'Rahilly, S. 2005. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J. Clin. Endocrinol. Metab. 90:1446-1452.
85. Nakamura, Y., et al. 1998. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol. 123:675-682.
86. Satoh, H., et al. 1999. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem. Biophys. Res. Commun. 254:757-763.
87. Tsai, Y.S., et al. 2004. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest. 114:240-249. doi:10.1172/JCI200318012.
88. Freedman, B.D., Lee, E.J., Park, Y., and Jameson, J.L. 2005. A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome. J. Biol. Chem. 280:17118-17125.
89. Semple, R.K., et al. 2005. A dominant negative human peroxisome proliferator-activated receptor (PPAR)alpha is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology. 146:1871-1882.
90. Savage, D.B., et al. 2002. Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet. 31:379-384.
91. Kubota, N., et al. 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
92. Miles, P.D., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105:287-292.
93. Altshuler, D., et al. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:76-80.
94. Stumvoll, M., and Haring, H. 2002. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 51:2341-2347.
95. Deeb, S.S., et al. 1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
96. Masugi, J., Tamori, Y., Mori, H., Koike, T., and Kasuga, M. 2000. Inhibitory effect of a proline-toalanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun. 268:178-182.
97. Poulsen, P., et al. 2003. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes. 52:194-198.
98. Andrulionyte, L., Zacharova, J., Chiasson, J.L., and Laakso, M. 2004. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 47:2176-2184.
99. Memisoglu, A., et al. 2003. Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes. Diabetes Care. 26:2915-2917.
100. Ek, J., et al. 2001. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia. 44:1170-1176.
101. Zouari Bouassida, K., et al. 2005. The peroxisome proliferator activated receptorgamma2 (PPARgamma2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab. 31:119-123.
102. Malecki, M.T., et al. 2003. The Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res. Clin. Pract. 62:105-111.
103. Poirier, O., Nicaud, V., Cambien, F., and Tiret, L. 2000. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J. Mol. Med. 78:346-351.
104. Oh, E.Y., et al. 2000. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J. Clin. Endocrinol. Metab. 85:1801-1804.
105. Cole, S.A., et al. 2000. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int. J. Obes. Relat. Metab. Disord. 24:522-524.
106. Beamer, B.A., et al. 1998. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes. 47:1806-1808.
107. Valve, R., et al. 1999. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84:3708-3712.
108. Meirhaeghe, A., Cottel, D., Amouyel, P., and Dallongeville, J. 2005. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes. 54:3043-3048.
109. Meirhaeghe, A., et al. 2005. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol. Genet. Metab. 85:140-148.
110. Doney, A., et al. 2002. Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 3:21.
111. Memisoglu, A., et al. 2003. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum. Mol. Genet. 12:2923-2929.
112. Robitaille, J., Despres, J.P., Perusse, L., and Vohl, M.C. 2003. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin. Genet. 63:109-116.
113. Luan, J., et al. 2001. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes. 50:686-689.
114. Nicklas, B.J., et al. 2001. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes. 50:2172-2176.
115. Lindi, V., et al. 2003. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 FA supplementation. Mol. Genet. Metab. 79:52-60.
116. Adamo, K.B., et al. 2005. Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia. 48:1503-1509.
117. Ostergard, T., et al. 2005. Influence of the PPARgamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. Horm. Metab. Res. 37:99-105.
118. Weiss, E.P., et al. 2005. Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-gamma2 Pro12Ala genotype in men but not in women. Metabolism. 54:97-102.
119. Kahara, T., et al. 2003. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism. 52:209-212.
120. Franks, P.W., et al. 2004. Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism. 53:11-16.
121. Tschritter, O., et al. 2003. Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala. Metabolism. 52:778-783.
122. Stumvoll, M., et al. 2001. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes. 50:876-881.
123. Schneider, J., Kreuzer, J., Hamann, A., Nawroth, P.P., and Dugi, K.A. 2002. The proline 12 alanine substitution in the peroxisome proliferator- activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes. 51:867-870.
124. Mousavinasab, F., et al. 2005. Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men. Mol. Genet. Metab. 84:344-348.
125. Takata, N., et al. 2004. Pro12Ala substitution in peroxisome proliferator-activated receptor gamma 2 is associated with low adiponectin concentrations in young Japanese men. Metabolism. 53:1548-1551.